Company Filing History:
Years Active: 2003
Title: Innovator Spotlight: Jonathan Cagampang Heller from San Francisco, CA
Introduction: Jonathan Cagampang Heller is a notable inventor based in San Francisco, California, who has made significant contributions to the field of genetic modifications through his pioneering patents. With a total of two patents to his name, Heller's innovative work focuses on invertebrate vascular endothelial growth factor receptor and TWIK channel nucleic acids and proteins. His research is paving the way for advancements in therapeutic applications and agricultural pest control.
Latest Patents: Heller's latest patents include:
1. **Invertebrate Vascular Endothelial Growth Factor Receptor:** This patent describes the discovery of nucleic acids and proteins, particularly the vascular endothelial growth factor receptor (dmVEGFR), isolated from invertebrates. These dmVEGFR nucleic acids and proteins can be utilized to genetically modify metazoan invertebrate organisms, such as insects and worms, resulting in the expression or mis-expression of dmVEGFR. The genetically modified organisms or cultured cells derived from this research can be used in screening assays to identify candidate compounds for potential therapeutics that interact with the dmVEGFR protein. Moreover, they serve as valuable tools for studying dmVEGFR activity and discovering additional genes that modulate its function.
2. **Nucleic Acids and Polypeptides of Invertebrate TWIK Channels:** This patent elaborates on tandem pore domain weak inward rectifying K (TWIK) channel nucleic acids and proteins isolated from various invertebrates, including Leptinotarsa. Similar to his previous patent, these TWIK channel nucleic acids and proteins can be used to genetically modify metazoan invertebrate organisms and cultured cells, allowing for the expression or mis-expression of the TWIK channel. The genetically modified organisms have the potential to be used in screening assays for identifying novel pesticidal agents or therapeutics. Additionally, this research aids in the examination of TWIK channel activity and in pinpointing other genes that interact with it.
Career Highlights: Jonathan Cagampang Heller currently works at Exelixis, Inc., a company known for its commitment to discovering new therapies for cancer and other serious diseases. His work greatly contributes to the company’s innovative drug development programs. Notably, Heller holds two patents that reflect his expertise in molecular biology and genetic engineering.
Collaborations: Heller collaborates with talented coworkers, including John William Winslow and Andrew Roy Buchman. Together, they share insights and knowledge that enhance their research endeavors and drive the advancement of science in their field.
Conclusion: Jonathan Cagampang Heller stands as a remarkable inventor whose work on invertebrate vascular endothelial growth factor receptors and TWIK channels demonstrates the potential for genetic modification in various applications. His endeavors at Exelixis, Inc. contribute to groundbreaking advancements that may lead to new therapeutic options and pest control measures in agriculture. With a keen focus on innovation, Heller continues to inspire the scientific community with his inventive spirit and commitment to research.